癌度医学临床招募资讯微信群（点击）我们对于恶性肿瘤的靶向药治疗效果存在误区，比如认为将靶向药使用之后应该是立竿见影见效才对，事实上任何的靶向药只有部分患者有效果。我们还会认为靶向药可以一直持续用下去，事实上靶向药会存在耐药的问题（这就是中位无进展生存 ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

EGFR 20 外显子插入（EGFR ex20ins）突变是非小细胞肺癌（NSCLC）中除 EGFR 19 外显子缺失（19-Del）和 21 外显子 L858R 点突变（21-L858R）两大常见突变外的 EGFR ...

At AACR 2025, Lunit will showcase its latest AI-driven approach to predicting EGFR mutations in NSCLC—in collaboration with ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

This surge reflects the increasing reliance on genetic diagnostics for identifying hereditary diseases, guiding cancer ...

Among the most common EGFR mutations detected in test results are the EGFR exon 19 deletion and the EGFR L858R point mutation. In non-small cell lung cancer, targeted therapies primarily focus on EGFR ...

So, this is how osimertinib will be used in the NHS. People with EGFR mutation-positive NSCLC whose tumours have been surgically removed (complete resection) have the option of then having ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung ...

It specifically targets epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), according to the National Institute for Health and Care Excellence (Nice).